Morningstar® Stock Report™

Novartis AG NOVN

Letzte Unternehmensnews

DatumZeitQuelleTitelTyp
Previous Stories...
29.01.202006:00NASDAQNEWSNovartis delivered strong sales growth, margin expansion and breakthrough innovation launching five NMEs in 2019ACS
06.01.202006:00NASDAQNEWSNovartis completes tender offer for all outstanding shares of The Medicines CompanyACQ
16.12.201906:15NASDAQNEWSNovartis provides update on LUSTER Phase III studies in patients with uncontrolled GINA 4/5 asthmaRES
05.12.201906:00NASDAQNEWSNovartis tender offer for The Medicines Company commencesTEN
24.11.201920:00NASDAQNEWSNovartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of deathACQ
15.11.201920:06NASDAQNEWSNew Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell diseaseRES
01.11.201906:15NASDAQNEWSNovartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritisRES
30.10.201906:00NASDAQNEWSNovartis announces AVXS-101 intrathecal study updateRES
22.10.201905:00NASDAQNEWSNovartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in USQRT
08.10.201905:15NASDAQNEWSNovartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs afliberceptPRL
02.10.201905:15NASDAQNEWSNovartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrumRES
29.09.201914:30NASDAQNEWSNovartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patientsRES
17.09.201905:15NASDAQNEWSNovartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritisRES
30.08.201905:15NASDAQNEWSNovartis ofatumumab demonstrates superiority versus Aubagio® in two head-to-head Phase III multiple sclerosis studiesRES
29.07.201905:00NASDAQNEWSNovartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)RES
18.07.201905:00NASDAQNEWSNovartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increasedADH
01.07.201915:30NASDAQNEWSNovartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolioADH
07.06.201905:00NASDAQNEWSNovartis announces new leader of Pharmaceuticals Business UnitADH
26.05.201922:00NASDAQNEWSFDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancerADH
24.05.201916:41NASDAQNEWSAveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and FamiliesADH